Navigation Links
Jiangbo Pharmaceuticals Reaffirms Guidance for Fiscal 2009
Date:9/8/2009

LAIYANG, China, Sept. 8 /PRNewswire-Asia-FirstCall/ -- Jiangbo Pharmaceuticals, Inc. (OTC Bulletin Board: JGBO) (the "Company", "Jiangbo"), a U.S. pharmaceutical company with its principal operations in the People's Republic of China, today reaffirmed its previously announced guidance for fiscal year 2009. The Company expects to meet or exceed its goals of $111 to $116 million in revenue and operating income of $40 to $43 million for the fiscal year ending June 30, 2009.

"We plan to report our annual results for the fiscal year 2009 by the end of this month and are pleased to reaffirm we are on track to achieve our financial goals," said Mr. Wubo Cao, Chief Executive Officer of Jiangbo. "We continue to revamp the production lines which we acquired from Hongrui earlier this year. We expect this project to be completed in May 2010, when we should be able to begin mass production of other profitable TCM products. Thus, we continue to feel confident in maintaining a healthy growth rate over the long term."

About Jiangbo Pharmaceuticals, Inc.

Jiangbo Pharmaceuticals, Inc. is a U.S. public company engaged in the research, development, production, marketing and sales of pharmaceutical products in the People's Republic of China. Its operations are located in Eastern China in an Economic Development Zone in Laiyang City, Shandong province. Jiangbo is a major pharmaceutical company in China producing both western and Chinese herbal-based medical drugs in tablet, capsule, granule, syrup and electuary (sticky syrup) form. http://www.jiangbopharma.com

Safe Harbor Statement

Certain statements in this press release that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the Company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties. Actual results may differ materially from anticipated or predicted results, and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's ability to obtain raw materials needed in manufacturing, the continuing employment of key employees, the failure risks inherent in testing any new drug, the possibility that regulatory approvals may be delayed or become unavailable, patent or licensing concerns that may include litigation, direct competition from other manufacturers and product obsolescence. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.

    For more information, please contact:

    Jiangbo Pharmaceuticals, Inc.
     Ms. Elsa Sung, CFO
     Phone: +1-954-727-8435
     Email: elsasung@jiangbo.com
     Web:  http://www.jiangbopharma.com

    CCG Investor Relations, Inc.
     Mr. Crocker Coulson, President
     Phone: +1-646-213-1915
     Email: crocker.coulson@ccgir.com
     Web:  http://www.ccgirasia.com

'/>"/>
SOURCE Jiangbo Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Jiangbo Pharmaceuticals to Present at Rodman & Renshaw Annual Global Investment Conference
2. Onyx Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
3. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
4. Amylin Pharmaceuticals to Present at Morgan Stanley Global Healthcare Unplugged Conference
5. Adamas Pharmaceuticals to Present Data on Triple Combination Antiviral Drug Therapy for Drug-Resistant Influenza at 2009 ICAAC Annual Meeting
6. Oramed Pharmaceuticals to Present at Rodman & Renshaw 11th Annual Healthcare Conference
7. NovaBay(R) Pharmaceuticals to Present at Rodman & Renshaw 11th Annual Healthcare Conference September 10, 2009 in New York City
8. Optimer Pharmaceuticals to Present at September 2009 Investor Conferences
9. Arena Pharmaceuticals to Present at the Rodman & Renshaw Annual Global Investment Conference
10. OncoGenex Pharmaceuticals to Webcast Presentations at September Investor Conferences
11. Onyx Pharmaceuticals to Present at Two Upcoming Healthcare Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... ... 2017 , ... LabRoots , the leading provider of educational and interactive ... to announce the launch of a new scholarship for young scientists seeking a degree ... scholarship is open to all high school seniors, 17 years or older; as well ...
(Date:2/22/2017)... Aethlon Medical, Inc. (Nasdaq: AEMD ... validated the ability of the Aethlon Hemopurifier® to capture ... in immune-suppressed sepsis patients and also contribute to organ ... of the study was to validate the in ... and Herpes Simplex virus 1 (HSV1) by the Hemopurifier®. ...
(Date:2/22/2017)... PHOENIX and SAN DIEGO ... Technology Holdings (the "Company") (OTCQB:CELZ) announced today expansion ... universal donor stem cell product through establishment of ... initiated research activities at the San Diego BioLabs ... Companies, Boehringer Ingelheim, Novartis, and Sanofi. ...
(Date:2/21/2017)... Feb. 21, 2017 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or the ... results for the three months ended December 31, 2016. ... life sciences and diagnostics company that develops and commercializes proprietary ... ... build on the commercial milestones achieved in fiscal 2016," said ...
Breaking Biology Technology:
(Date:1/25/2017)... YORK , Jan. 25, 2017 The ... Access Management (IAM) lifecycle is comprised of a ... for the purpose of maintaining digital identities and ... resources and applications. There are significant number of ... from time to time by optimizing processes and ...
(Date:1/23/2017)... -- The latest mobile market research from Acuity Market Intelligence ... quarterly average price of a biometric smartphone decreased from ... There are now 120 sub-$150 models on the market ... 28 a year ago at an average price of ... , Acuity Market Intelligence Principal, "Biometric Smartphones are a ...
(Date:1/19/2017)... , Jan. 19, 2017 Sensory ... experience and security for consumer electronics, and ... processing systems and cybersecurity solutions, today announced a ... and financial institutions worldwide to bolster security of ... end-to-end secure user authentication platforms they offer, innerCore ...
Breaking Biology News(10 mins):